Glucose-Insulin-Potassium Infusion in Patients With Acute Myocardial Infarction Without Signs of Heart Failure: The Glucose-Insulin-Potassium Study (GIPS)-II  by Timmer, Jorik R. et al.
11. Schachinger V, Assmus B, Britten MB, et al. Transplantation of
progenitor cells and regeneration enhancement in acute myocardial
infarction: final one-year results of the TOPCARE-AMI Trial. J Am
Coll Cardiol 2004;44:1690–9.
12. De Bruyne B, Pijls NHJ, Bartunek J, et al. Fractional flow reserve
in patients with prior myocardial infarction. Circulation 2001;104:
157–62.
13. De Bruyne B, Hersbach F, Pijls NHJ, et al. Abnormal epicardial
coronary resistance in patients with diffuse atherosclerosis but “normal”
coronary angiography. Circulation 2001;104:2401–6.
14. Richel DJ, Johnsen HE, Canon J, et al. Highly purified CD34 cells
isolated using magnetically activated cell selection provide rapid
engraftment following high-dose chemotherapy in breast cancer pa-
tients. Bone Marrow Transplant 2000;25:243–9.
Glucose-Insulin-Potassium Infusion in Patients With Acute Myocardial Infarction Without
Signs of Heart Failure: The Glucose-Insulin-Potassium Study (GIPS)-II
To the Editor: Metabolic support through glucose-insulin-
potassium (GIK), in adjunct to reperfusion therapy, might improve
outcome in patients with ST-segment elevation myocardial infarc-
tion (STEMI) (1). The Glucose-Insulin-Potassium Study
(GIPS)-I showed clinical benefit of GIK in STEMI patients
without signs of heart failure (2). To verify these findings we
performed a second study investigating GIK in patients without
signs of heart failure treated with reperfusion therapy.
It concerns a randomized, open label study (3); STEMI
patients without signs of heart failure on admission were
randomized to traditional care or additional GIK infusion.
Glucose-potassium (20% glucose with 80 mmol potassium/l)
was infused at 2 ml/kg body weight per hour for 12 h through
a peripheral line. Short-acting insulin was started according to
admission glucose and adjusted on the basis of hourly measured
glucose.
Primary end point was 30-day mortality. Enzymatic infarct size
was estimated by the highest value of creatine kinase (peak CK).
Multivariate analyses (including all univariate predictors and GIK
intervention) were performed to identify independent predictors of
30-day mortality (Cox regression) and high enzymatic infarct size
(logistic regression). A sample size of 1,044 patients was planned,
on the basis of the mortality reduction in non-heart-failure
patients as reported in GIPS-I (1.2% vs. 4.2%) (2).
Patient inclusion started August 2003. After planned interim
analysis, the study was terminated in December 2004, because a
significant difference was unlikely to be reached on further inclusion.
A total of 889 patients were included (Table 1). Anterior
infarct location was more common in the GIK group, and
previous percutaneous coronary intervention (PCI) more com-
mon in the control group. All other general characteristics were
comparable between the two treatment groups. Reperfusion ther-
apy consisted of primary PCI (n  778, 88%) or thrombolysis (n 
65). Mean starting insulin dose in the GIK group was 9.6 7.5 U/h.
During 30 days’ follow-up, 13 patients (2.9%) died in the GIK group
and 8 patients (1.8%) died in the control group (odds ratio [OR] 1.6;
95% confidence interval [CI]: 0.7 to 4.0, p  0.27) (Fig. 1).
Multivariate analyses showed that failed reperfusion, anterior infarct
location, and higher admission glucose but not GIK infusion (OR 1.5;
95% CI: 0.6 to 3.9) were independent predictors of 30-day mortality.
Mean peak CK was 2,008  1,930 U/l in patients treated with
GIK compared with 1,932  1,847 U/l in control subjects (p 
0.57). The prevalence of a high enzymatic infarct size (CK levels
in the upper tertile [2,149 U/l]) was comparable between
patients treated with GIK and control subjects (34% vs. 32%, p 
0.57). Multivariate analysis did not change these findings.
We could not confirm the previously observed benefit of GIK
in STEMI patients without signs of heart failure. Because the
sample size of the GIPS-II trial was based on the results of the
GIPS-I trial, it was not powered to demonstrate smaller
benefits of GIK; however, not even a trend toward a therapeutic
benefit was observed in our trial. Combined with the results of
other trials, it can be concluded that, in the used regimen, GIK
in adjunct to reperfusion therapy in STEMI patients does not
lower mortality.
Previous reports on the effect of GIK in STEMI have been
contradictory. The meta-analysis of Fath-Ordoubadi and Beatt
(4) showed a benefit of GIK infusion; however, studies included
in this meta-analysis were of older date, and none of the
Table 1. Baseline Characteristics of the Patient Groups
GIK Group
(n  444)
Control Group
(n  445) p Value
Age (yrs) 61.8  12.4 61.2  12.3 0.51
Age 60 yrs 242 (55%) 243 (55%) 0.98
Men 326 (73%) 329 (74%) 0.86
Previous MI 37 (8%) 54 (12%) 0.06
Previous PCI 27 (6%) 48 (11%) 0.01
Previous CABG 6 (1%) 11 (3%) 0.22
Diabetes 41 (9%) 46 (10%) 0.57
Diabetes using insulin 12 (3%) 10 (2%) 0.66
Hypertension 146 (33%) 125 (28%) 0.13
Positive family history 190 (46%) 201 (48%) 0.57
Systolic blood pressure
(mm Hg)
135.3  25.7 132.5  24.0 0.11
Diastolic blood pressure
(mm Hg)
80.5  15.9 79.0  15.0 0.18
Anterior infarction 210 (48%) 172 (39%) 0.01
Ischemic time 229  143 220  112 0.31
Reperfusion therapy 418 (94%) 426 (96%) 0.28
Primary PCI 391 (88%) 387 (87%)
Rescue PCI 23 (6%) 26 (6%)
Thrombolysis 4 (1%) 12 (3%)
Reperfusion successful 395 (95%) 404 (95%) 0.83
Mean glucose on
admission (mmol/l)
8.5  2.8 8.3  2.5 0.51
Discharge medication in
the patient groups
Aspirin 422 (95%) 415 (93%) 0.26
Coumadin 17 (4%) 19 (4%) 0.74
Clopidrogel 396 (89%) 391 (88%) 0.54
Beta-blocker 402 (91%) 384 (86%) 0.048
Statin 392 (88%) 387 (87%) 0.55
ACE inhibitor 261 (59%) 251 (56%) 0.47
Oral anti-glycemic agent 25 (6%) 28 (6%) 0.68
Insulin 12 (3%) 15 (3%) 0.56
ACE  angiotensin-converting enzyme; CABG  coronary artery bypass grafting;
GIK  glucose insulin potassium; MI  myocardial infarction; PCI  percutaneous
coronary intervention.
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patients received reperfusion therapy. Most studies published
after this meta-analysis only showed benefit of GIK in specific
subgroups. The Estudios Cardiologicos Latinoamerica (ECLA)
study demonstrated mortality reduction in the sub-group
treated with reperfusion therapy (5). The Polish-Glucose-
Insulin-Potassium (Pol-GIK) trial was prematurely stopped,
because mortality was significantly higher in GIK patients (6).
The GIPS-I trial, including only patients treated with primary
PCI, found a mortality reduction in patients without heart
failure on admission (2). The Clinical Trial of Reviparin and
Metabolic Modulation in Acute Myocardial Infarction Treat-
ment Evaluation (CREATE)-ECLA study, with a sample size
of 20,201 patients, showed only a trend toward a better outcome
in the patients (n  1,831) treated with primary PCI (7). The
only study to date showing a clinical benefit of (glucose-)
insulin was the Diabetes Mellitus Insulin-Glucose Infusion in
Acute Myocardial Infarction (DIGAMI) study; however, this
study included hyperglycemic patients and was primarily aimed
at reduction of glucose levels (8).
There might be several explanations for the lack of effects of
GIK in STEMI. Experimental evidence suggests a beneficial
effect of GIK by shifting myocardial free fatty acid metabolism
toward glucose metabolism. This is less oxygen-consuming and
produces less toxic side products (1). Furthermore, reperfusion
injury might be reduced by limiting apoptosis of post-ischemic
myocardial cells; however, once adequate reperfusion has been
established, GIK might be of limited value, because maximal
myocardial salvage has already taken place. Furthermore, gly-
cometabolic support might only be beneficial when it is aimed
at lowering glucose levels in patients with severe derangement
of glucose metabolism, as in the DIGAMI study (8). In
addition, side effects of GIK infusion include hyperglycemia,
hyperkalemia, and fluid overload. This might diminish the
potential benefits.
Although there is no role for GIK in routine practice of patients
with STEMI, there remain several issues to be clarified. Admin-
istering concentrated GIK through a central line might diminish
adverse effects of fluid overload. Starting GIK before reperfusion
therapy, during ambulance transportation for example, and GIK
regimens specifically aimed at euglycemia should be further inves-
tigated (8,9).
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APPENDIX
For a list of the Steering Committee and the participating
hospitals and cardiologists, please see the online version of
this article.
Figure 1. Thirty-day survival according to randomization. GIK 
glucose-insulin-potassium.
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